High interstitial fluid pressure - an obstacle in cancer therapy - PubMed (original) (raw)
Review
doi: 10.1038/nrc1456.
Affiliations
- PMID: 15510161
- DOI: 10.1038/nrc1456
Review
High interstitial fluid pressure - an obstacle in cancer therapy
Carl-Henrik Heldin et al. Nat Rev Cancer. 2004 Oct.
Abstract
Many solid tumours show an increased interstitial fluid pressure (IFP), which forms a barrier to transcapillary transport. This barrier is an obstacle in tumour treatment, as it results in inefficient uptake of therapeutic agents. There are a number of factors that contribute to increased IFP in the tumour, such as vessel abnormalities, fibrosis and contraction of the interstitial matrix. Lowering the tumour IFP with specific signal-transduction antagonists might be a useful approach to improving anticancer drug efficacy.
Similar articles
- Time-dependent behavior of interstitial fluid pressure in solid tumors: implications for drug delivery.
Netti PA, Baxter LT, Boucher Y, Skalak R, Jain RK. Netti PA, et al. Cancer Res. 1995 Nov 15;55(22):5451-8. Cancer Res. 1995. PMID: 7585615 - Effects of the vascular disrupting agent ZD6126 on interstitial fluid pressure and cell survival in tumors.
Skliarenko JV, Lunt SJ, Gordon ML, Vitkin A, Milosevic M, Hill RP. Skliarenko JV, et al. Cancer Res. 2006 Feb 15;66(4):2074-80. doi: 10.1158/0008-5472.CAN-05-2046. Cancer Res. 2006. PMID: 16489007 - Improving delivery of antineoplastic agents with anti-vascular endothelial growth factor therapy.
Yang AD, Bauer TW, Camp ER, Somcio R, Liu W, Fan F, Ellis LM. Yang AD, et al. Cancer. 2005 Apr 15;103(8):1561-70. doi: 10.1002/cncr.20942. Cancer. 2005. PMID: 15754332 Review. - Uptake of IgG in osteosarcoma correlates inversely with interstitial fluid pressure, but not with interstitial constituents.
de Lange Davies C, Engesaeter BØ, Haug I, Ormberg IW, Halgunset J, Brekken C. de Lange Davies C, et al. Br J Cancer. 2001 Dec 14;85(12):1968-77. doi: 10.1054/bjoc.2001.2180. Br J Cancer. 2001. PMID: 11747342 Free PMC article. - Critical issues in site-specific targeting of solid tumours: the carrier, the tumour barriers and the bioavailable drug.
Hamad I, Moghimi SM. Hamad I, et al. Expert Opin Drug Deliv. 2008 Feb;5(2):205-19. doi: 10.1517/17425247.5.2.205. Expert Opin Drug Deliv. 2008. PMID: 18248319 Review.
Cited by
- Emerging Antineoplastic Biogenic Gold Nanomaterials for Breast Cancer Therapeutics: A Systematic Review.
Saravanan M, Vahidi H, Medina Cruz D, Vernet-Crua A, Mostafavi E, Stelmach R, Webster TJ, Mahjoub MA, Rashedi M, Barabadi H. Saravanan M, et al. Int J Nanomedicine. 2020 May 19;15:3577-3595. doi: 10.2147/IJN.S240293. eCollection 2020. Int J Nanomedicine. 2020. PMID: 32547015 Free PMC article. - The use of therapeutic peptides to target and to kill cancer cells.
Boohaker RJ, Lee MW, Vishnubhotla P, Perez JM, Khaled AR. Boohaker RJ, et al. Curr Med Chem. 2012;19(22):3794-804. doi: 10.2174/092986712801661004. Curr Med Chem. 2012. PMID: 22725698 Free PMC article. Review. - Immuno-PET of epithelial ovarian cancer: harnessing the potential of CA125 for non-invasive imaging.
Sharma SK, Wuest M, Wang M, Glubrecht D, Andrais B, Lapi SE, Wuest F. Sharma SK, et al. EJNMMI Res. 2014 Dec;4(1):60. doi: 10.1186/s13550-014-0060-4. Epub 2014 Nov 12. EJNMMI Res. 2014. PMID: 26116121 Free PMC article. - Combination of the STING Agonist MIW815 (ADU-S100) and PD-1 Inhibitor Spartalizumab in Advanced/Metastatic Solid Tumors or Lymphomas: An Open-Label, Multicenter, Phase Ib Study.
Meric-Bernstam F, Sweis RF, Kasper S, Hamid O, Bhatia S, Dummer R, Stradella A, Long GV, Spreafico A, Shimizu T, Steeghs N, Luke JJ, McWhirter SM, Müller T, Nair N, Lewis N, Chen X, Bean A, Kattenhorn L, Pelletier M, Sandhu S. Meric-Bernstam F, et al. Clin Cancer Res. 2023 Jan 4;29(1):110-121. doi: 10.1158/1078-0432.CCR-22-2235. Clin Cancer Res. 2023. PMID: 36282874 Free PMC article. Clinical Trial. - PDGF-BB modulates hematopoiesis and tumor angiogenesis by inducing erythropoietin production in stromal cells.
Xue Y, Lim S, Yang Y, Wang Z, Jensen LD, Hedlund EM, Andersson P, Sasahara M, Larsson O, Galter D, Cao R, Hosaka K, Cao Y. Xue Y, et al. Nat Med. 2011 Dec 4;18(1):100-10. doi: 10.1038/nm.2575. Nat Med. 2011. PMID: 22138754
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources